Table 2 Longitudinal variations of the cohort
From: Metabolic remodeling in glioblastoma: a longitudinal multi-omics study
Characteristics | Inclusiona n = 34 | Week 6a n = 34 | Progressiona n = 34 | p-valuea |
|---|---|---|---|---|
Overall Survival (months) | 13 (10–17) | |||
Progression free survival (months) | 6.0 (5.0–6.8) | |||
Corticoid treatment (mg/j) | 35 (0–40) | 40 (20–75) | 40 (20–80) | |
Bactrim | 0/34 (0%) | 23/34 (68%) | 0/34 (0%) | |
Hemoglobin (g/dl) | 14.4 (13.8–15.3) | 13.20 (12.5–14.6) | 13.10 (11.5–14.4) | |
Leucocytes (G/L) | 9.0 (7.6–12.3) | 7.4 (5.8–10.0) | 6.2 (5.6–8.7) | |
Platelets (G/L) | 271 (230–320) | 214 (149–239) | 177 (148–214) | < 0.001 |
Albumin | 44.0 (42.0–46.0) | 42.0 (40.0–44.0) | 40.0 (37.5–44.0) | 0.004 |
Prothrombin time | 1.12 (1.03–1.18) | 1.09 (0.96–1.20) | 1.10 (1.04–1.23) | |
Creatinine (µmol/L) | 66 (60–75) | 72 (62–82) | 64 (52–72) |